| Name | Canlitinib |
|---|---|
| Synonyms | Hexanoic acid, 6-[[4-[2-fluoro-4-[[[1-[[(4-fluorophenyl)amino]carbonyl]cyclopropyl]carbonyl]amino]phenoxy]-6-methoxy-7-quinolinyl]oxy] |
| Description | Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C33H31F2N3O7 |
|---|---|
| Molecular Weight | 619.61 |